Clinical Trial Update: Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating secukinumab 300 mg and 150 mg versus placebo in adults with active psoriatic arthritis after 16 weeks of treatment; stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriatic Arthritis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriatic Arthritis | Phase 4 | Status: COMPLETED | Results posted: 2021-01-28